🔗 Share this article

A senior health officer has been recused of involvement in a major medical study concerning gender-affirming medication after allegations regarding bias emerged.

Reported Involvement Led to Study Pause

As reported by news accounts, Prof Jacob George, a chief medical director for the medicines regulator, raised issues that caused the pausing of a government-funded Pathways trial during the winter.

This regulator stated recently how George would recuse himself of participation in the study once questioning online comments made last year came to light.

Nature of Online Posts

In one comment, he described author the Harry Potter author as an asset in modern society.” Separately, he stated that the refusal of basic biological fact is concerning” in relation to questions over a elite boxer’s gender.

This agency clarified that although the comments were posted prior to his official position, he was recused of oversight in the study as a abundance of caution.

Particulars of the Paused Clinical Study

The research project, that was intended to assess the effect of puberty blockers on young people questioning their gender, was set to begin recruiting participants during the start of the year.

Yet, it was suspended during February once the regulatory body expressed apprehensions regarding the safety for young participants taking part.

• Its youngest subjects were anticipated to be ten to eleven for biological females and eleven to twelve for assigned male at birth.
• Its trial team stated previously that the rigorous screening process indicated participants would probably be more mature.
• However, officials has now said the lowest age requirement should be 14 due to the unknown danger” of enduring health consequences.”

The research had planned to enroll a projected two hundred and twenty-six youths over the following three years.

Context and a Cass Review

The trial was commissioned subsequent to a suggestion by an independent inquiry on children’s gender identity services, that determined how the quality of the studies purporting to demonstrate the advantages of this type of medication for children experiencing gender incongruence was weak.”

Doctor Hilary Cass, who chaired the review, had earlier said the findings exposed an extremely poor evidence base” supporting the benefits of puberty blockers.

She continued, “given that there are clinicians, children and families who believe deeply in the helpful results, research remained the only way ahead to make sense of this.”

Expert Criticism of the Action

Doctor Max Davie, a child health specialist, argued there was no compelling scientific reason to suspend the research.

“The social media posts by Prof George offer a clear indication into his individual stance on this issue,” he stated. “The professor is free to have any opinions about gender identity he may, however what is unacceptable is permit these opinions to influence the execution of his official role.”

He concluded: “For clarity, there exists no definitive scientific reason to halt this study. While Prof George’s own views are not the only plausible cause for the regulator’s unexpected volte-face, they are the sole instance where we possess proof.”

Regulator Statement and Next Steps

A MHRA representative said: “With all clinical trials, our foremost duty is the safety and wellbeing for the volunteers. In line with that commitment, detailed studies remain continuously under review and the MHRA maintains a continuous conversation with study funders.”

“We have expert medical, scientific and regulatory experts who function as a multidisciplinary group to make research-informed decisions on medical research. This team will continue to meet with the research team to work through the next steps productively.”

“Subsequent to the identification of social media posts made before he took up his role, Professor Jacob George was recused of any additional oversight regarding this clinical trial as a preventative step.”